Lixte Biotechnology (NASDAQ:LIXT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ:AMEX Investor Relations:
lixte.com/investor_information_02.php
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
LIXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIXT alerts
High impacting Lixte Biotechnology Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LIXT
News
- LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer TreatmentGlobeNewswire
- LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3GlobeNewswire
- LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition PlansGlobeNewswire
- LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT) [Yahoo! Finance]Yahoo! Finance
- LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions [Yahoo! Finance]Yahoo! Finance
LIXT
Sec Filings
- 11/28/25 - Form 25-NSE/A
- 11/25/25 - Form 8-K
- 11/12/25 - Form 10-Q
- LIXT's page on the SEC website